Ovid Therapeutics (OVID) Price to Sales (2020 - 2026)

Ovid Therapeutics (OVID) has reported Price to Sales for 7 consecutive years, with 678.03 the latest figure, recorded in Q2 2026.

• For the quarter ending Q2 2026, Price to Sales rose 18022.19% year-over-year to 678.03; the trailing twelve-month figure through Jun 2026 stood at 313.96 (up 8798.45% YoY), and the FY2025 full-year result was 16.57, down 85.8% from the prior year.
• Price to Sales rose to 678.03 in Q2 2026 per OVID's latest filing, from 167.4 in the prior quarter.
• Across five years, Price to Sales topped out at 11678.89 in Q3 2022 and bottomed at 3.74 in Q2 2025.
• Historically, Price to Sales has averaged 1840.94 across 5 years, with a median of 784.84 in 2024.
• The sharpest annual moves came in 2025 and 2026: Price to Sales sank 98.84% in 2025, then surged 18022.19% in 2026.
• Over 5 years, Price to Sales stood at 2832.07 in 2022, then tumbled by 43.4% to 1603.02 in 2023, then sank by 45.79% to 868.94 in 2024, then sank by 80.74% to 167.4 in 2025, then jumped by 305.04% to 678.03 in 2026.
• According to Business Quant data, Price to Sales over the past three periods registered 678.03, 167.4, and 700.74 for Q2 2026, Q4 2025, and Q3 2025 respectively.